Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 9/20 | 0.40 |
| ▸ | ACHE | P22303 | 3/20 | 0.35 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14152325 | 0.86 | CES1 (0.41) | CES1ACHEBCHE | |
| SCHEMBL32662523 | 0.79 | ACHE (0.33) | ACHEBCHE | |
| SCHEMBL4121408 | 0.76 | ACHE (0.32) | ACHE | |
| SCHEMBL31684557 | 0.72 | OPRL1 (0.47) | — | |
| SCHEMBL21447816 | 0.72 | CES1 (0.33) | CES1 | |
| SCHEMBL31684425 | 0.71 | OPRM1 (0.39) | ACHE | |
| SCHEMBL31684552 | 0.71 | AKT1 (0.36) | ACHE | |
| SCHEMBL2472184 | 0.70 | CES1 (0.33) | CES1 | |
| SCHEMBL4270535 | 0.69 | CYP2A6 (0.43) | HCAR1 | |
| SCHEMBL30705553 | 0.69 | GRIA1 (0.33) | CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | TRAWSFYNYDD THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015337-A1 | COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION | ACE2, ACE, TMPRSS2 | CES1 50/4885ACHE 844/4885HCAR1 573/4885 |
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | CES1 1370/4885ACHE 78/4885HCAR1 720/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.